|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Beal EW, Tumin D, Moris D, Zhang XF,
Chakedis J, Dilhoff M, Schmidt CM and Pawlik TM: Cohort
contributions to trends in the incidence and mortality of
intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr.
7:270–276. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee YT, Wang JJ, Luu M, Noureddin M,
Nissen NN, Patel TC, Roberts LR, Singal AG, Gores GJ and Yang JD:
Comparison of clinical features and outcomes between intrahepatic
cholangiocarcinoma and hepatocellular carcinoma in the United
States. Hepatology. 74:2622–2632. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abdel-Rahman O, Elsayed Z and Elhalawani
H: Gemcitabine-based chemotherapy for advanced biliary tract
carcinomas. Cochrane Database Syst Rev. 4:CD0117462018.PubMed/NCBI
|
|
5
|
Pellino A, Loupakis F, Cadamuro M,
Dadduzio V, Fassan M, Guido M, Cillo U, Indraccolo S and Fabris L:
Precision medicine in cholangiocarcinoma. Transl Gastroenterol
Hepatol. 3:402018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cragg GM and Newman DJ: Natural products:
A continuing source of novel drug leads. Biochim Biophys Acta.
1830:3670–3695. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Harvey AL, Edrada-Ebel R and Quinn RJ: The
re-emergence of natural products for drug discovery in the genomics
era. Nat Rev Drug Discov. 14:111–129. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Newman DJ and Cragg GM: Natural products
as sources of new drugs from 1981 to 2014. J Nat Prod. 79:629–661.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Trenti A, Zulato E, Pasqualini L,
Indraccolo S, Bolego C and Trevisi L: Therapeutic concentrations of
digitoxin inhibit endothelial focal adhesion kinase and
angiogenesis induced by different growth factors. Br J Pharmacol.
174:3094–3106. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Patel S: Plant-derived cardiac glycosides:
Role in heart ailments and cancer management. Biomed Pharmacother.
84:1036–1041. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang YZ, Chen X, Fan XX, He JX, Huang J,
Xiao DK, Zhou YL, Zheng SY, Xu JH, Yao XJ, et al: Compound library
screening identified cardiac glycoside digitoxin as an effective
growth inhibitor of gefitinib-resistant non-small cell lung cancer
via downregulation of alpha-tubulin and inhibition of microtubule
formation. Molecules. 21:3742016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee DH, Lee CS, Kim DW, Ae JE and Lee TH:
Digitoxin sensitizes glioma cells to TRAIL-mediated apoptosis by
upregulation of death receptor 5 and downregulation of survivin.
Anticancer Drugs. 25:44–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu M, Feng LX, Sun P, Liu W, Mi T, Lei M,
Wu W, Jiang B, Yang M, Hu L, et al: Knockdown of Apolipoprotein E
Enhanced sensitivity of Hep3B cells to cardiac steroids via
regulating Na+/K+-ATPase signalosome. Mol Cancer Ther.
15:2955–2965. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pollard BS, Suckow MA, Wolter WR, Starr
JM, Eidelman O, Dalgard CL, Kumar P, Battacharyya S, Srivastava M,
Biswas R, et al: Digitoxin inhibits
Epithelial-to-Mesenchymal-Transition in hereditary castration
resistant prostate cancer. Front Oncol. 9:6302019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fan Q, Li M, Zhao W, Zhang K, Li M and Li
W: Hyper alpha2,6-sialylation promotes CD4(+) T-cell activation and
induces the occurrence of ulcerative colitis. Adv Sci (Weinh).
10:e23026072023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye L, Jia Y, Ji KE, Sanders AJ, Xue K, Ji
J, Mason MD and Jiang WG: Traditional Chinese medicine in the
prevention and treatment of cancer and cancer metastasis. Oncol
Lett. 10:1240–1250. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiang Y, Guo Z, Zhu P, Chen J and Huang Y:
Traditional Chinese medicine as a cancer treatment: Modern
perspectives of ancient but advanced science. Cancer Med.
8:1958–1975. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yan Z, Lai Z and Lin J: Anticancer
properties of traditional Chinese medicine. Comb Chem High
Throughput Screen. 20:423–429. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu HA, Chen CH, Hsieh MH, Wu YC, Chiu JP,
Huang CJ and Hsu CH: The Benefit of Enhanced daycare of traditional
Chinese medicine for cancer treatment related adverse events: A
retrospective study of medical records. Integr Cancer Ther.
20:153473542110256342021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
You L, Lin J, Yu Z, Qian Y, Bi Y, Wang F,
Zhang L, Zheng C, Zhang J, Li W, et al: Nobiletin suppresses
cholangiocarcinoma proliferation via inhibiting GSK3β. Int J Biol
Sci. 18:5698–5712. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu Q, Shi X, Pan Y, Liao X, Xu J, Gu X, Yu
W, Chen Y and Yu G: The chemopreventive role of β-Elemene in
cholangiocarcinoma by restoring PCDH9 expression. Front Oncol.
12:8744572022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang JKT, Portbury S, Thomas MB, Barney S,
Ricca DJ, Morris DL, Warner DS and Lo DC: Cardiac glycosides
provide neuroprotection against ischemic stroke: Discovery by a
brain slice-based compound screening platform. Proc Natl Acad Sci
USA. 103:10461–10466. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prassas I and Diamandis EP: Novel
therapeutic applications of cardiac glycosides. Nat Rev Drug
Discov. 7:926–935. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Botelho AFM, Pierezan F, Soto-Blanco B and
Melo MM: A review of cardiac glycosides: Structure, toxicokinetics,
clinical signs, diagnosis and antineoplastic potential. Toxicon.
158:63–68. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wei WL, An YL, Zhang YZ, Li ZW, Zhou Y,
Lei M, Zhang JQ, Qu H, Da J, Wu WY and Guo DA: Quantitative
analysis of fourteen bufadienolides in Venenum bufonis crude
drug and its Chinese patent medicines by ultra-high performance
liquid chromatography coupled with tandem mass spectrometry. J
Ethnopharmacol. 251:1124902020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kumavath R, Paul S, Pavithran H, Paul MK,
Ghosh P, Barh D and Azevedo V: Emergence of cardiac glycosides as
potential drugs: Current and future scope for cancer therapeutics.
Biomolecules. 11:12752021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mi C, Cao X, Ma K, Wei M, Xu W, Lin Y,
Zhang J and Wang TY: Digitoxin promotes apoptosis and inhibits
proliferation and migration by reducing HIF-1α and STAT3 in KRAS
mutant human colon cancer cells. Chem Biol Interact.
351:1097292022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eldawud R, Wagner A, Dong C, Gupta N,
Rojanasakul Y, O'Doherty G, Stueckle TA and Dinu CZ: Potential
antitumor activity of digitoxin and user-designed analog
administered to human lung cancer cells. Biochim Biophys Acta Gen
Subj. 1864:1296832020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jagielska J, Salguero G, Schieffer B and
Bavendiek U: Digitoxin elicits anti-inflammatory and vasoprotective
properties in endothelial cells: Therapeutic implications for the
treatment of atherosclerosis? Atherosclerosis. 206:390–396. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Whitaker RH and Cook JG: Stress relief
techniques: p38 MAPK determines the balance of cell cycle and
apoptosis pathways. Biomolecules. 11:14442021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li F and Ding J: Sialylation is involved
in cell fate decision during development, reprogramming and cancer
progression. Protein Cell. 10:550–565. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Scott E, Archer Goode E, Garnham R,
Hodgson K, Orozco-Moreno M, Turner H, Livermore K, Putri Nangkana
K, Frame FM, Bermudez A, et al: ST6GAL1-mediated aberrant
sialylation promotes prostate cancer progression. J Pathol.
261:71–84. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Smithson M, Irwin R, Williams G, Alexander
KL, Smythies LE, Nearing M, McLeod MC, Al Diffalha S, Bellis SL and
Hardiman KM: Sialyltransferase ST6GAL-1 mediates resistance to
chemoradiation in rectal cancer. J Biol Chem. 298:1015942022.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hait NC, Maiti A, Wu R, Andersen VL, Hsu
CC, Wu Y, Chapla DG, Takabe K, Rusiniak ME, Bshara W, et al:
Extracellular sialyltransferase st6gal1 in breast tumor cell growth
and invasiveness. Cancer Gene Ther. 29:1662–1675. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ambrosy AP and Gheorghiade M: Targeting
digoxin dosing to serum concentration: Is the bullseye too small?
Eur J Heart Fail. 18:1082–1084. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Belz GG, Breithaupt-Grogler K and Osowski
U: Treatment of congestive heart failure-current status of use of
digitoxin. Eur J Clin Invest. 31 (Suppl 2):S10–S17. 2001.
View Article : Google Scholar
|
|
38
|
Lopez-Lazaro M, Pastor N, Azrak SS, Ayuso
MJ, Cortes F and Austin CA: Digitoxin, at concentrations commonly
found in the plasma of cardiac patients, antagonizes etoposide and
idarubicin activity in K562 leukemia cells. Leuk Res. 30:895–898.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bavendiek U, Berliner D, Dávila LA, Schwab
J, Maier L, Philipp SA, Rieth A, Westenfeld R, Piorkowski C, Weber
K, et al: Rationale and design of the DIGIT-HF trial (DIGitoxin to
Improve ouTcomes in patients with advanced chronic Heart Failure):
A randomized, double-blind, placebo-controlled study. Eur J Heart
Fail. 21:676–684. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lopez-Lazaro M, Pastor N, Azrak SS, Ayuso
MJ, Austin CA and Cortes F: Digitoxin inhibits the growth of cancer
cell lines at concentrations commonly found in cardiac patients. J
Nat Prod. 68:1642–1645. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Daniel D, Susal C, Kopp B, Opelz G and
Terness P: Apoptosis-mediated selective killing of malignant cells
by cardiac steroids: Maintenance of cytotoxicity and loss of
cardiac activity of chemically modified derivatives. Int
Immunopharmacol. 3:1791–1801. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bohmer T and Roseth A: Prolonged digitoxin
half-life in very elderly patients. Age Ageing. 27:222–224. 1998.
View Article : Google Scholar : PubMed/NCBI
|
